Keyphrases
Tumor-infiltrating Lymphocytes
97%
Melanoma
55%
T Cells
47%
Tumor
45%
CD8+ T Cells
37%
Neoantigen
31%
CD4+
30%
Metastatic Melanoma
29%
Clinical Outcomes
27%
Cancer Immunotherapy
24%
Tumor-specific
21%
Adoptive Cell Therapy
21%
Neoantigen Vaccine
21%
Neoepitope
21%
Nivolumab
21%
Peptide-based
21%
Acquired Resistance
21%
T Cell Activation
20%
Tumor Killing
18%
Immune Checkpoint Inhibitors
18%
Tumor Microenvironment
16%
Tumor Cells
15%
Antigen-specific T Cell Response
15%
Tumor-specific Immune Response
15%
Corticosteroids
14%
IFN Signaling
14%
Tumor Regression
14%
Anti-PD-1 Therapy
13%
Dose Level
13%
Personalized Therapy
13%
Tocilizumab
12%
Immune-related Adverse Events
12%
Tumor Subtype
12%
Tumor-specific T Cells
11%
Costimulatory Molecules
11%
Checkpoint Inhibition
11%
Autologous Tumor Antigens
11%
Checkpoint Pathway
10%
Human CD8+ T Cells
10%
Phase II Study
10%
Ipilimumab
10%
Stereotactic Body Radiotherapy
10%
Renal Cell Carcinoma
10%
IrAE
10%
Regulation Strategy
10%
Brain Metastases
10%
JAK Signaling
10%
Pancreatic Cancer
10%
T-cell Receptor Repertoire
10%
Checkpoint Inhibitors
10%
Immunology and Microbiology
Tumor-Infiltrating Lymphocytes
100%
T Cell
95%
Cytotoxic T-Cell
35%
Neoantigen
35%
CD4
25%
Immune Response
24%
Cancer Immunotherapy
24%
Immunotherapy
23%
Vaccine Efficacy
21%
Tumor Necrosis Factor
21%
Carcinoma Cell
21%
Nivolumab
21%
T Cell Receptor
21%
Tumor Cell
20%
CD8
17%
Upregulation
13%
Tocilizumab
12%
Transcriptomics
12%
Tumor Antigen
11%
T Cell Activation
11%
MHC Class I
10%
Antigen Presentation
10%
Tacrolimus
10%
Point Mutation
10%
Adjuvant
10%
Ipilimumab
10%
Antigen Specificity
10%
Frameshift Mutation
10%
Cell Activity
10%
Dynamics
10%
Natural Killer Cell
10%
Human Leukocyte Antigen
10%
Dexamethasone
9%
Drug Megadose
9%
Immune Escape
8%
Immunocompetent Cell
7%
Lymphocyte Activation
7%
Infliximab
7%
Beta-2 Microglobulin
7%
Indel Mutation
7%
Lymphocyte
7%
Mycophenolic Acid
6%
Programmed Cell Death 1
6%
T-Helper Cell
6%
Immunity
6%
Immune Checkpoint Blockade
5%
Tumor Cell Line
5%
Whole Exome Sequencing
5%
Medicine and Dentistry
Neoplasm
58%
T Cell
46%
Tumor Infiltrating Lymphocyte
43%
Nodular Melanoma
33%
Immunotherapy
21%
Immune Checkpoint Inhibitor
16%
Cytotoxic T-Cell
14%
Metastatic Melanoma
14%
Transcriptomics
13%
Clinical Trial
11%
Cancer Immunotherapy
11%
Tumor Cell
11%
Malignant Neoplasm
10%
Brain Metastasis
10%
Receptor
10%
Point Mutation
10%
Frameshift Mutation
10%
Ipilimumab
10%
Adjuvant
10%
Tumor Regression
10%
Stereotactic Body Radiation Therapy
10%
Antigen Presentation
10%
Clear Cell Renal Cell Carcinoma
10%
Personalized Medicine
10%
Tocilizumab
10%
Nivolumab
10%
Pancreas Cancer
10%
Diseases
10%
Uvea Melanoma
10%
Biopsy Technique
10%
Human Leukocyte Antigen
10%
Natural Killer Cell
10%
CD8 Antigen
9%
Immune Response
9%
Tumor Microenvironment
8%
Disease
7%
Specific Tumor
7%
T-Cell Response
7%
Janus Kinase 1
7%
Beta 2 Microglobulin
7%
Immune Checkpoint Blockade
6%
Lymphocyte Activation
6%
Immunity
6%
Cell Mediated Cytotoxicity
5%
Progressive Disease
5%
Infusion
5%
